Display options
Cite
Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett. 2007;582(1):26-31doi: 10.1016/j.febslet.2007.11.040.
Reilly, S. M., & Lee, C. H. (2008). PPAR delta as a therapeutic target in metabolic disease. FEBS letters, 582(1), 26-31. https://doi.org/10.1016/j.febslet.2007.11.040
Reilly, Shannon M, and Lee, Chih-Hao. "PPAR delta as a therapeutic target in metabolic disease." FEBS letters vol. 582,1 (2008): 26-31. doi: https://doi.org/10.1016/j.febslet.2007.11.040
Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett. 2008 Jan 09;582(1):26-31. doi: 10.1016/j.febslet.2007.11.040. Epub 2007 Nov 26. PMID: 18036566; PMCID: PMC2275052.
Copy Download .nbib Format: NLM
Share it on

FEBS Lett. 2008 Jan 09;582(1):26-31. doi: 10.1016/j.febslet.2007.11.040. Epub 2007 Nov 26.

PPAR delta as a therapeutic target in metabolic disease.

FEBS letters

Shannon M Reilly, Chih-Hao Lee

Affiliations

  1. Department of Genetics and Complex Diseases, Harvard University School of Public Health, 665 Huntington Avenue, Bldg 2, Room 119, Boston, MA 02115-5818, USA.

PMID: 18036566 PMCID: PMC2275052 DOI: 10.1016/j.febslet.2007.11.040

Abstract

PPAR delta is the only member in the PPAR subfamily of nuclear receptors that is not a target of current drugs. Animal studies demonstrate PPAR delta activation exerts many favorable effects, including reducing weight gain, increasing skeletal muscle metabolic rate and endurance, improving insulin sensitivity and cardiovascular function and suppressing atherogenic inflammation. These activities stem largely from the ability of PPAR delta to control energy balance, reduce fat burden and protect against lipotoxicity caused by ectopic lipid deposition. Therefore, PPAR delta represents a novel therapeutic target and the development of PPAR delta gonists/modulators may be useful for treating the whole spectrum of metabolic syndrome.

References

  1. Mol Cell Biol. 2000 Jul;20(14):5119-28 - PubMed
  2. Nature. 2006 Dec 14;444(7121):860-7 - PubMed
  3. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1268-73 - PubMed
  4. J Biol Chem. 1995 Jun 2;270(22):12953-6 - PubMed
  5. Dig Dis Sci. 2007 Nov;52(11):2912-9 - PubMed
  6. Mol Cell Biol. 1995 Jun;15(6):3012-22 - PubMed
  7. Nature. 2002 Aug 15;418(6899):797-801 - PubMed
  8. Cell. 2001 Feb 23;104(4):503-16 - PubMed
  9. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3444-9 - PubMed
  10. Eur J Pharmacol. 2006 Apr 24;536(1-2):182-91 - PubMed
  11. Cell. 1999 Oct 29;99(3):335-45 - PubMed
  12. Science. 2003 Oct 17;302(5644):453-7 - PubMed
  13. Int J Obes (Lond). 2006 Dec;30(12):1709-13 - PubMed
  14. Oncogene. 2004 Nov 25;23(55):8992-6 - PubMed
  15. Nature. 2002 Dec 19-26;420(6917):868-74 - PubMed
  16. N Engl J Med. 2002 Aug 8;347(6):417-29 - PubMed
  17. Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19069-74 - PubMed
  18. Curr Atheroscler Rep. 2007 Jan;9(1):72-7 - PubMed
  19. Science. 1992 May 1;256(5057):668-70 - PubMed
  20. Diabetes. 2004 Mar;53(3):847-51 - PubMed
  21. Endocrinology. 2003 Jun;144(6):2201-7 - PubMed
  22. Atherosclerosis. 2005 Jul;181(1):29-37 - PubMed
  23. Cell. 1995 Dec 15;83(6):835-9 - PubMed
  24. Endocr Rev. 1999 Oct;20(5):649-88 - PubMed
  25. Nat Med. 2004 Nov;10(11):1245-50 - PubMed
  26. Kidney Int. 2006 Nov;70(9):1560-6 - PubMed
  27. Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):359-65 - PubMed
  28. Mol Cell. 2002 Oct;10(4):721-33 - PubMed
  29. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):303-8 - PubMed
  30. J Clin Invest. 2006 Nov;116(11):3015-25 - PubMed
  31. Science. 1997 Mar 21;275(5307):1787-90 - PubMed
  32. Science. 2001 Nov 30;294(5548):1866-70 - PubMed
  33. J Clin Invest. 2003 Dec;112(12):1821-30 - PubMed
  34. Am J Med. 2006 May;119(5 Suppl 1):S10-6 - PubMed
  35. FEBS Lett. 2000 May 19;473(3):333-6 - PubMed
  36. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5306-11 - PubMed
  37. Diabetologia. 2006 Oct;49(10):2350-8 - PubMed
  38. Cell Metab. 2006 Nov;4(5):407-14 - PubMed
  39. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15924-9 - PubMed
  40. PLoS Biol. 2004 Oct;2(10):e294 - PubMed
  41. J Clin Invest. 2004 Dec;114(11):1564-76 - PubMed
  42. FASEB J. 2003 Dec;17(15):2299-301 - PubMed
  43. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2434-9 - PubMed
  44. J Clin Invest. 2003 Dec;112(12):1796-808 - PubMed
  45. Nat Med. 2004 May;10(5):481-3 - PubMed
  46. Cell. 2003 Apr 18;113(2):159-70 - PubMed
  47. Nat Rev Immunol. 2003 Jul;3(7):521-33 - PubMed
  48. Mol Cell Biol. 2006 Apr;26(8):3266-81 - PubMed
  49. Nat Med. 2004 Mar;10(3):245-7 - PubMed

Substances

MeSH terms

Publication Types

Grant support